Workers need to adapt more quickly than in the past and continue to do so throughout their careers. Traditional workforce upskilling and reskilling methods are evolving as well, driven by new educational delivery systems, intelligent technologies, and …
Intent data shows you which companies are actively researching your products, but implementing and using it effectively can be a challenge. Download your free eBook to learn: What intent data is and the different types The key benefits of…
Get tips on driving sustainability, innovation, and a hybrid-work model in your business.Request Free!
Intent data shows you which companies are actively researching your products, but implementing and using it effectively can be a challenge. Download your free eBook to learn: What intent data is and the different types The key benefits of…
How can you help your students succeed in an environment where employer needs are constantly changing? Get the latest findings and put them into practice now. This new report on Industry 4.0 reflects leading-edge research—and provides informed, a…
Gain an understanding of how consumers – both those identifying as LGBTQ+ and not – experience content, and the implications of these findings for brand growth, now and in the future.Request Free!
An image says more than a thousand words – and a video more than a thousand pieces of marketing material. Today’s tech marketers understand the importance of video: other than a live personal interaction, nothing tells a story, informs, and commun…
You’re a sharp brand marketer with multiple goals and a toolkit of promotions to achieve them. But when and why do you give your customers rewards versus discounts at checkout—and how important is this today? Research from branded payment e…
Big Four FaaS Market Study New data underscores the critical role that outsourcing plays in the overall finance and accounting market today. The global market for finance and accounting outsourcing — also sometimes referred to as Finance as a …
Drugmakers and, largely, the FDA argue that the medicines now being reviewed are different than the chemotherapies and blunter interventions of the past. This is having consequences for how clinical trials are being run, and for how much money drugmake…
